Five-Day TMS Protocol Matches Six-Week Treatment for Depression in UCLA Study

Transcranial magnetic stimulation has been one of the more reliable tools available for patients who cycle through antidepressants without success. Large clinical studies have shown it reduces symptoms in 60 to 70 percent of treatment-resistant cases and achieves remission in 25 to 35 percent. The barrier has never been efficacy - it has been time. Six weeks of daily clinic visits, five days a week, is a schedule that many patients simply cannot maintain.

A study published in the Journal of Affective Disorders by researchers at UCLA Health raises the possibility that this barrier may not be as fixed as once assumed. The trial compared outcomes between 135 patients who received standard TMS - one session per day for six weeks - and 40 who completed an accelerated protocol: five sessions per day for five consecutive days. Both groups showed clinically meaningful reductions in depression symptoms, and when researchers ran the statistical comparison, the difference between them did not reach significance.

The five-by-five protocol and what it demands

The accelerated schedule, sometimes called "5x5," compresses 25 TMS treatments into a single work week. Each session is brief, but attending five per day requires patients to stay at or near the clinic for extended periods. For some, that concentrated commitment is far more manageable than returning every weekday for a month and a half - particularly for people in demanding jobs, those who lack reliable transportation, or patients traveling from outside the area.

"For patients with treatment-resistant depression, getting to the clinic every weekday for at least six weeks can be a real obstacle," said Michael Apostol, a Ph.D. student at the UCLA Semel Institute for Neuroscience and Human Behavior and lead author of the study. "What this study suggests is that we may be able to offer those same patients a path to meaningful relief in less than one week by condensing 25 TMS treatments over just five days."

All 175 patients enrolled in the study had failed to benefit from multiple antidepressant medication trials before entering the research. That baseline matters: these are not mild cases. They represent the population where alternatives are most urgently needed.

Delayed response in the accelerated group

One of the more clinically significant findings involved a subset of patients in the 5x5 arm who appeared to show little improvement immediately after finishing their five-day course. When the research team followed up two to four weeks later, those same patients showed a 36 percent average reduction in depression scores.

This delayed response pattern has direct implications for how clinicians should counsel patients after completing the accelerated schedule. A patient who finishes five days of treatment and feels no different may still be in the process of responding.

"All patients in this study had not benefitted from multiple trials of antidepressant medication, yet they obtained great benefit from 5x5 treatment," said senior author Dr. Andrew Leuchter, distinguished professor and director of the TMS Service of the UCLA Department of Psychiatry and Biobehavioral Sciences. "Some patients need to wait a few days or weeks to see benefit, and we encourage them not to give up too quickly if they don't feel better right away."

Leuchter also noted that adding one or two supplementary sessions at the two-week mark appeared to enhance outcomes further, though the study did not conduct a formal randomized comparison of this add-on approach.

Where the standard protocol still leads

The six-week approach retained advantages on some longer-term outcome measures. That is not a peripheral finding. TMS carries a well-established track record precisely because the conventional protocol has been tested in large, controlled trials with rigorous follow-up periods. The current UCLA study was not a randomized controlled trial - patients were not randomly assigned to either group. Instead, clinicians and patients selected the protocol based on individual circumstances, which introduces potential selection bias.

The 40-patient accelerated group is also small relative to the 135-patient conventional group. Modest sample sizes can produce statistically non-significant differences even when real differences exist, particularly when there is high variability in individual responses - a defining feature of depression research.

The authors acknowledged these limitations directly and called for larger, randomized controlled trials to confirm the findings before 5x5 TMS could be considered equivalent to the standard schedule in clinical guidelines.

Insurance coverage and access

TMS is currently covered under most insurance plans for treatment-resistant depression, but that coverage is built around the conventional protocol. Accelerated schedules occupy a grayer area in terms of billing and reimbursement. How insurers will respond to 5x5 TMS as evidence accumulates is an open question, and one that will substantially shape whether the compressed schedule can reach patients who might benefit from it.

The UCLA team is also exploring TMS applications beyond depression, including obsessive-compulsive disorder and chronic pain. Those expansions, if supported by future trials, would position the technology as part of a broader clinical toolkit for conditions affecting brain function and behavior.

For now, the study adds a meaningful data point to an active debate about how much the structure of TMS therapy can be modified without sacrificing its effects. The answer, at least in this cohort, appears to be: more than previously assumed.